Skip to content
2000
Volume 11, Issue 3
  • ISSN: 1871-5230
  • E-ISSN: 1875-614X

Abstract

Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.

Loading

Article metrics loading...

/content/journals/aiaamc/10.2174/187152312804142803
2012-12-01
2025-05-24
Loading full text...

Full text loading...

/content/journals/aiaamc/10.2174/187152312804142803
Loading

  • Article Type:
    Research Article
Keyword(s): adverse effects; cystic fibrosis; Inhaled corticosteroids
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test